Redwood Pharma enters partnership with Nextec medical in preparation for European market clearance of RP501
Stockholm, Sweden, December 15, 2022. Redwood Pharma AB (publ) has entered a partnership with Nextec medical GmbH to act as the Legal Manufacturer for Redwood Pharma´s medical device RP501. The partnership is an important step to ensure a time and resource efficient pathway to obtain CE-mark and facilitate the market introduction of RP501 for the treatment of dry eye disease.Redwood Pharma’s medical device RP501 is being developed as an effective over-the-counter tear substitute for temporary relief of dry eye disease, a medical condition affecting more than 300 million people around the